Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Adenocarcinoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.

The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.

Risk Map Decision Support System (DSS).

A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.

Magnetic Resonance Imaging (MRI)

A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.

Magnetic Resonance Imaging (MRI) Guided Biopsy

Aytekin Oto, MD

Cancer Intake Team

Aytekin Oto

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Compare the accuracy of the Risk Map Decision Support Systems (DSS) tool against the clinical accuracy of experienced radiologists in the context of the reference standard of biopsy histology.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy	NCT05710380	Prostate Cancer Prostate Adenoc... Prostate Neopla...	Risk Map Decisi... Magnetic Resona... Magnetic Resona...	18 Years -	University of Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy	NCT05710380	Prostate Cancer Prostate Adenoc... Prostate Neopla...	Risk Map Decisi... Magnetic Resona... Magnetic Resona...	18 Years -	University of Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy	NCT05710380	Prostate Cancer Prostate Adenoc... Prostate Neopla...	Risk Map Decisi... Magnetic Resona... Magnetic Resona...	18 Years -	University of Chicago

Spots Global Cancer Trial Database for magnetic resonance imaging (mri) guided biopsy